363 results on '"Gyorki, David E."'
Search Results
52. Development of melanoma clinical quality indicators for the Australian melanoma clinical outcomes registry ( MelCOR ): A modified Delphi study
53. Characterization of the treatment-naive immune microenvironment in melanoma with BRAF mutation
54. Optimising the quality of multidisciplinary team meetings: A narrative review
55. Prospective evaluation of prognostic indicators for early recurrence of cutaneous melanoma
56. International Center-Level Variation in Utilization of Completion Lymph Node Dissection and Adjuvant Systemic Therapy for Sentinel Lymph Node Positive Melanoma at Major Referral Centers
57. Second-line immunotherapy in patients with metastatic melanoma
58. Publisher Correction: Single-cell profiling of breast cancer T cells reveals a tissue-resident memory subset associated with improved prognosis
59. Post-operative survival following metastasectomy for patients receiving BRAF inhibitor therapy is associated with duration of pre-operative treatment and elective indication
60. Immunological Insights from Patients Undergoing Surgery on Ipilimumab for Metastatic Melanoma
61. Prophylactic Central Neck Dissection in Differentiated Thyroid Cancer: An Assessment of the Evidence
62. Cutaneous squamous cell carcinoma metastatic to the axilla and groin: Outcomes and prognostic factors
63. Tumor reactivity of CD8 + T cells favors acquisition of dysfunctional states in human melanoma
64. Current management of advanced melanoma: a transformed landscape
65. Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers
66. A survey of surgical management of the sentinel node positive melanoma patient in the post‐MSLT2 era
67. Contemporary management of locoregionally advanced melanoma in Australia and New Zealand and the role of adjuvant systemic therapy
68. Desmoplastic Melanoma: A Pathologically and Clinically Distinct Form of Cutaneous Melanoma
69. Ptpn2 and KLRG1 regulate the generation and function of tissue-resident memory CD8+ T cells in skin
70. Active surveillance of patients who have sentinel node positive melanoma: An international, multi‐institution evaluation of adoption and early outcomes after the Multicenter Selective Lymphadenectomy Trial II (MSLT‐2)
71. Management of Recurrent Retroperitoneal Sarcoma
72. Sentinel Lymph Node Biopsy for Patients With Cutaneous Desmoplastic Melanoma
73. Improving the impact of didactic resident training with online spaced education
74. Cancer Surgery in Low-Income Countries: An Unmet Need
75. Spontaneous bacterial peritonitis: a rare mimic of acute appendicitis
76. The role of 18 F‐FDG PET/CT in retroperitoneal sarcomas—A multicenter retrospective study
77. Generating CAR T cells from tumor-infiltrating lymphocytes
78. Systemic Therapy for Melanoma: ASCO Guideline
79. Comment on “Factors Affecting Sentinel Node Metastasis in Thin (T1) Cutaneous Melanomas: Development and External Validation of a Predictive Nomogram”
80. Efficacy of immune checkpoint inhibitors for in-transit melanoma
81. Colaboradores
82. MACROPHAGES, MORE THAN JUST SCAVENGERS: THEIR ROLE IN BREAST DEVELOPMENT AND CANCER
83. Laudable pus: historic concept revisited
84. Cutaneous squamous cell carcinoma metastatic to the axilla and groin: Outcomes and prognostic factors.
85. Management of Primary Retroperitoneal Sarcoma (RPS) in the Adult: An Updated Consensus Approach from the Transatlantic Australasian RPS Working Group.
86. Correlation between percutaneous biopsy and final histopathology for retroperitoneal sarcoma: a single‐centre study
87. Identifying challenges to implementation of clinical practice guidelines for sentinel lymph node biopsy in patients with melanoma in Australia: protocol paper for a mixed methods study
88. Skin colonization with beta papilloma virus drives tissue immunity and resistance to squamous cell cancer
89. An evidence-based approach to positive sentinel node disease: should we ever do a completion node dissection?
90. Systemic therapies for unresectable locoregional melanoma: a significant area of need
91. Locoregional melanoma: identifying optimal care in a rapidly changing landscape
92. The Prognosis and Natural History of In-Transit Melanoma Metastases at a High-Volume Centre
93. Characterizing high-grade serous papillary carcinoma of tunica vaginalis
94. Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium
95. Efficacy of immune checkpoint inhibitors (ICIs) for in-transit melanoma.
96. One-year (yr) recurrence-free survival (RFS) from a randomized, open label phase II study of neoadjuvant (neo) talimogene laherparepvec (T-VEC) plus surgery (surgx) versus surgx for resectable stage IIIB-IVM1a melanoma (MEL).
97. BRAFmutation testing for patients diagnosed with stage III or stage IV melanoma: practical guidance for the Australian setting
98. The role of 18F‐FDG PET/CT in retroperitoneal sarcomas—A multicenter retrospective study.
99. Accumulation of CD103 + CD8 + T cells in a cutaneous melanoma micrometastasis
100. Ectopic breast cancer in the inguinal region
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.